Mitumomab: Difference between revisions
Content deleted Content added
No edit summary |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
| (12 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = 458284525 |
| verifiedrevid = 458284525 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
<!-- Monoclonal antibody data --> |
||
| type = mab |
| type = mab |
||
| Line 9: | Line 10: | ||
| target = GD3 [[ganglioside]] |
| target = GD3 [[ganglioside]] |
||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| pregnancy_US = |
| pregnancy_US = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = |
||
| legal_CA = |
| legal_CA = |
||
| legal_UK = |
| legal_UK = |
||
| legal_US = |
| legal_US = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|correct|CAS}} |
||
| CAS_number = 216503-58-1 |
| CAS_number = 216503-58-1 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = KZ9WFQ2NXF |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| IUPHAR_ligand = 7981 |
| IUPHAR_ligand = 7981 |
||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| Line 39: | Line 42: | ||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Mitumomab''' ('''BEC-2''') is a [[mouse]] anti-BEC-2 [[monoclonal antibody]] investigated for the treatment of [[small cell lung carcinoma]] in combination with [[Bacillus Calmette-Guérin|BCG]] vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the [[immune system]]. It was developed by [[ImClone]] and [[Merck]].<ref>http://adisinsight.springer.com/drugs/800003245</ref> |
'''Mitumomab''' ('''BEC-2''') is a [[mouse]] anti-BEC-2 [[monoclonal antibody]] investigated for the treatment of [[small cell lung carcinoma]] in combination with [[Bacillus Calmette-Guérin|BCG]] vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the [[immune system]]. It was developed by [[ImClone]] and [[Merck Serono|Merck]].<ref>{{cite web|url=http://adisinsight.springer.com/drugs/800003245 |title=Mitumomab - AdisInsight |website=Adisinsight.springer.com |date=2005-06-13 |access-date=2017-01-06}}</ref> |
||
The first phase III [[clinical trial]] began in 1998.<ref>{{ClinicalTrialsGov|NCT00037713|Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG}}</ref><ref>{{ClinicalTrialsGov|NCT00006352|Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer |
The first phase III [[clinical trial]] began in 1998.<ref>{{ClinicalTrialsGov|NCT00037713|Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG}}</ref><ref>{{ClinicalTrialsGov|NCT00006352|Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer}}</ref> In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.<ref>{{cite journal | vauthors = Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, Rome L, Zatloukal P, Coens C, Giaccone G | display-authors = 6 | title = Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer | journal = European Journal of Cancer | volume = 44 | issue = 15 | pages = 2178–84 | date = October 2008 | pmid = 18676140 | doi = 10.1016/j.ejca.2008.06.036 }}</ref><ref>{{cite journal | vauthors = Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C | display-authors = 6 | title = Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) | journal = Journal of Clinical Oncology | volume = 23 | issue = 28 | pages = 6854–64 | date = October 2005 | pmid = 16192577 | doi = 10.1200/JCO.2005.17.186 | doi-access = free }}</ref> |
||
==See also== |
== See also == |
||
*[[Anti-ganglioside antibodies]] |
* [[Anti-ganglioside antibodies]] |
||
==References== |
== References == |
||
{{Reflist}} |
|||
{{cleanup-link rot}} |
|||
{{reflist}} |
|||
{{Monoclonals for tumors}} |
{{Monoclonals for tumors}} |
||
| Line 59: | Line 61: | ||
[[Category:Experimental cancer drugs]] |
[[Category:Experimental cancer drugs]] |
||
[[Category:Abandoned drugs]] |
[[Category:Abandoned drugs]] |
||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
Latest revision as of 23:52, 14 June 2023
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | GD3 ganglioside |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]
The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]
See also
[edit]References
[edit]- ^ "Mitumomab - AdisInsight". Adisinsight.springer.com. 2005-06-13. Retrieved 2017-01-06.
- ^ Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
- ^ Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
- ^ Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. (October 2008). "Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer". European Journal of Cancer. 44 (15): 2178–84. doi:10.1016/j.ejca.2008.06.036. PMID 18676140.
- ^ Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. (October 2005). "Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)". Journal of Clinical Oncology. 23 (28): 6854–64. doi:10.1200/JCO.2005.17.186. PMID 16192577.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |